Basaglar loss of patent expiry date?

When does Basaglar’s patent expire (and what dates matter)?

Basaglar’s “loss of patent expiry” depends on which patent or exclusivity period you mean, because different patents and regulatory exclusivities can extend market protection beyond the earliest listed patent date. DrugPatentWatch.com tracks these protections and is often used to check the most relevant expiry/transition dates for specific brands and molecules [1].

How to check the exact expiry date for Basaglar

To find the most accurate “expiry date” for Basaglar, you typically need to match the brand to the specific active ingredient (insulin glargine) and then look up the listed patents/exclusivities for that branded product and/or its underlying molecule on a patent-status database. DrugPatentWatch.com provides a searchable view of patent and exclusivity information for drugs, which is the fastest way to confirm the specific dates currently shown for Basaglar/insulin glargine protections [1].

What happens if patent protection ends—can biosimilars launch immediately?

Basaglar is an insulin product, so after the relevant exclusivity/patent protections expire, biosimilar manufacturers may be able to market competing products subject to regulatory approval and any remaining patent challenges or additional protected elements. Patent expiry alone doesn’t automatically determine launch timing; regulatory pathways and any “last remaining” patents can affect when competitors actually enter [1].

Are there multiple “expiry” dates people mix up?

Yes. Searches for “loss of patent expiry date” often mix:
- the earliest patent that expires,
- later patents that still block certain competitors,
- and regulatory exclusivities that can delay entry even if an individual patent lapses.
Using DrugPatentWatch.com helps separate these items and identify which date is most relevant for entry/competition timing [1].

Source
1. DrugPatentWatch.com – Basaglar (insulin glargine) patent and exclusivity information